- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00126477
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer
The Quality of Life of Adult Survivors Who Received a Marrow Transplant as a Child
RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of hematologic cancer and may help improve the quality of life for future cancer survivors.
PURPOSE: This clinical trial is studying the quality of life of adult cancer survivors who have undergone a previous bone marrow or peripheral stem cell transplant for a childhood hematologic cancer.
Panoramica dello studio
Stato
Descrizione dettagliata
OBJECTIVES:
- Determine the extent to which adult cancer survivors who have undergone prior bone marrow or peripheral blood stem cell transplantation for a pediatric hematologic malignancy require ongoing health care and whether these needs change with increasing time after transplantation.
- Correlate physical capabilities, body image, physical limitations, including sexuality issues which alter or influence lifestyle, with time after transplantation in these patients.
- Determine whether cognitive abilities relative to memory and neurobehavioral ratings change with increasing time after transplantation in these patients.
- Correlate social and relationship abilities with length of time after transplantation in these patients.
OUTLINE: Patients and siblings complete a self-report quality of life questionnaire, including outcome assessments of neuroendocrine function, cognitive abilities, physical capability, and psychosocial behavior.
PROJECTED ACCRUAL: Approximately 750 patients (375 adult cancer survivors [case group] and 375 siblings [control group]) will be accrued for this study within 7 years.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109-1024
- Fred Hutchinson Cancer Research Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Case group
Previously treated with an allogeneic, unrelated, syngeneic, or autologous bone marrow or peripheral blood stem cell transplantation for a hematologic malignancy ≥ 5 years ago while enrolled on 1 of the following protocols:
- FHCRC-160.06
- FHCRC-179.07T
- FHCRC-446.03T
- FHCRC-661.04
- FHCRC-697.00
- FHCRC-796.00
- FHCRC-843.00
- Disease-free survivor
- Under 18 years of age at time of transplantation
- Any prior preparative regimen allowed
Control group
- Sex-matched sibling within 5 years of patient's age*
- No chronic illnesses (e.g., cancer, diabetes, or asthma) that require medication
- No allergies that limit physical activity NOTE: *If such a sibling is not available, but another sibling is available, then that sibling would be asked to nominate a friend or relative of the same gender as the patient who is also within 5 years of the patient's age; the patient must consent in order for the control subject to participate
PATIENT CHARACTERISTICS:
Age
- See Disease Characteristics
- 18 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Must be able to speak, read, and write English
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Piano di studio
Come è strutturato lo studio?
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
|---|
|
Neuroendocrine status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18
|
|
Cognitive capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18
|
|
Physical capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18
|
|
Psychosocial status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Jean E. Sanders, MD, Fred Hutchinson Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- qualità della vita
- sindromi mielodisplastiche de novo
- sindromi mielodisplastiche precedentemente trattate
- sindromi mielodisplastiche secondarie
- leucemia linfoblastica acuta infantile in remissione
- leucemia mieloide acuta infantile in remissione
- leucemia mielomonocitica giovanile
- leucemia mieloide cronica infantile
- linfoma infantile a grandi cellule
- linfoma linfoblastico infantile
- linfoma infantile a piccole cellule non scisse
- linfoma di Hodgkin infantile
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Patologia
- Malattie del midollo osseo
- Malattie ematologiche
- Condizioni precancerose
- Linfoma
- Sindrome
- Sindromi mielodisplastiche
- Leucemia
- Preleucemia
Altri numeri di identificazione dello studio
- 1098.00
- FHCRC-1098.00
- CDR0000434793 (Identificatore di registro: PDQ)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .